JP2018500360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500360A5 JP2018500360A5 JP2017534314A JP2017534314A JP2018500360A5 JP 2018500360 A5 JP2018500360 A5 JP 2018500360A5 JP 2017534314 A JP2017534314 A JP 2017534314A JP 2017534314 A JP2017534314 A JP 2017534314A JP 2018500360 A5 JP2018500360 A5 JP 2018500360A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- halogen
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 293
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 117
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 116
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 112
- 150000002367 halogens Chemical class 0.000 claims description 89
- 150000003839 salts Chemical class 0.000 claims description 87
- 229910052736 halogen Inorganic materials 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000006413 ring segment Chemical group 0.000 claims description 71
- 125000001424 substituent group Chemical group 0.000 claims description 63
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 53
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 229910052760 oxygen Inorganic materials 0.000 claims description 42
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052717 sulfur Inorganic materials 0.000 claims description 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000004043 oxo group Chemical group O=* 0.000 claims description 19
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 18
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000002950 monocyclic group Chemical group 0.000 claims description 15
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims description 6
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims description 6
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 125000003003 spiro group Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N 2-hydroxyglutaric acid Chemical compound OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 102200069708 rs121913499 Human genes 0.000 claims description 2
- 102200069690 rs121913500 Human genes 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 0 CC(N1*)=C(*)C(*)=C(*S)C1=O Chemical compound CC(N1*)=C(*)C(*)=C(*S)C1=O 0.000 description 34
- 125000003545 alkoxy group Chemical group 0.000 description 34
- NODLZCJDRXTSJO-UHFFFAOYSA-N Cc1n[n](C)cc1 Chemical compound Cc1n[n](C)cc1 NODLZCJDRXTSJO-UHFFFAOYSA-N 0.000 description 14
- BLHTXORQJNCSII-UHFFFAOYSA-N Cc1c[n](C)cn1 Chemical compound Cc1c[n](C)cn1 BLHTXORQJNCSII-UHFFFAOYSA-N 0.000 description 13
- OBSLLHNATPQFMJ-UHFFFAOYSA-N Cc1c[s]c(C)n1 Chemical compound Cc1c[s]c(C)n1 OBSLLHNATPQFMJ-UHFFFAOYSA-N 0.000 description 12
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N Cc1cnc(C)[nH]1 Chemical compound Cc1cnc(C)[nH]1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 10
- PSOZJOZKEVZLKZ-UHFFFAOYSA-N Cc1c[o]c(C)n1 Chemical compound Cc1c[o]c(C)n1 PSOZJOZKEVZLKZ-UHFFFAOYSA-N 0.000 description 5
- WVUHHPQQQLBMOE-UHFFFAOYSA-N Cc1cnc(C)[s]1 Chemical compound Cc1cnc(C)[s]1 WVUHHPQQQLBMOE-UHFFFAOYSA-N 0.000 description 5
- HNJOAIYFUCQZAA-UHFFFAOYSA-N Cc1n[o]c(C)n1 Chemical compound Cc1n[o]c(C)n1 HNJOAIYFUCQZAA-UHFFFAOYSA-N 0.000 description 5
- PMCOWOCKUQWYRL-UHFFFAOYSA-N Cc1nc(C)ncc1 Chemical compound Cc1nc(C)ncc1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 5
- SZQCPPRPWDXLMM-UHFFFAOYSA-N Cc1c[n](C)nc1 Chemical compound Cc1c[n](C)nc1 SZQCPPRPWDXLMM-UHFFFAOYSA-N 0.000 description 4
- OJAWOLWHEQUTDE-UHFFFAOYSA-N Cc1c[n](C)nn1 Chemical compound Cc1c[n](C)nn1 OJAWOLWHEQUTDE-UHFFFAOYSA-N 0.000 description 4
- SDXAWLJRERMRKF-UHFFFAOYSA-N Cc1cc(C)n[nH]1 Chemical compound Cc1cc(C)n[nH]1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 4
- HVRBCXZGTURXBT-UHFFFAOYSA-N Cc1n[n](C)nn1 Chemical compound Cc1n[n](C)nn1 HVRBCXZGTURXBT-UHFFFAOYSA-N 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- BRAYYCBKNOERRJ-LURJTMIESA-N C[C@@H](C1)NCCN1C(C)=O Chemical compound C[C@@H](C1)NCCN1C(C)=O BRAYYCBKNOERRJ-LURJTMIESA-N 0.000 description 3
- PKDPUENCROCRCH-UHFFFAOYSA-N CC(N1CCNCC1)=O Chemical compound CC(N1CCNCC1)=O PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 2
- DJLDMYLDTWTWFR-OCAPTIKFSA-N CC(N1C[C@H](CC2)N[C@H]2C1)=O Chemical compound CC(N1C[C@H](CC2)N[C@H]2C1)=O DJLDMYLDTWTWFR-OCAPTIKFSA-N 0.000 description 2
- LJDKPLMEHLUQSN-UHFFFAOYSA-N CC1OC1N1CCNCC1 Chemical compound CC1OC1N1CCNCC1 LJDKPLMEHLUQSN-UHFFFAOYSA-N 0.000 description 2
- BRAYYCBKNOERRJ-ZCFIWIBFSA-N C[C@H](C1)NCCN1C(C)=O Chemical compound C[C@H](C1)NCCN1C(C)=O BRAYYCBKNOERRJ-ZCFIWIBFSA-N 0.000 description 2
- DMUZUGDIHVLUKC-PRJDIBJQSA-N CC(N(CCN1)C[C@H]1S)O Chemical compound CC(N(CCN1)C[C@H]1S)O DMUZUGDIHVLUKC-PRJDIBJQSA-N 0.000 description 1
- BAMPVSWRQZNDQC-UHFFFAOYSA-N Cc1c(C)[s]c(C)n1 Chemical compound Cc1c(C)[s]c(C)n1 BAMPVSWRQZNDQC-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095322P | 2014-12-22 | 2014-12-22 | |
| US62/095,322 | 2014-12-22 | ||
| PCT/US2015/067406 WO2016106331A1 (en) | 2014-12-22 | 2015-12-22 | Mutant idh1 inhibitors useful for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500360A JP2018500360A (ja) | 2018-01-11 |
| JP2018500360A5 true JP2018500360A5 (enExample) | 2019-02-07 |
| JP6901394B2 JP6901394B2 (ja) | 2021-07-14 |
Family
ID=55135546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534314A Active JP6901394B2 (ja) | 2014-12-22 | 2015-12-22 | 癌の処置に有用な変異型ｉｄｈ１阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10703746B2 (enExample) |
| EP (1) | EP3237385B1 (enExample) |
| JP (1) | JP6901394B2 (enExample) |
| CN (1) | CN107428690B (enExample) |
| AU (1) | AU2015369712B2 (enExample) |
| CA (1) | CA2971872C (enExample) |
| ES (1) | ES2905564T3 (enExample) |
| WO (1) | WO2016106331A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102209667B1 (ko) | 2014-09-19 | 2021-01-29 | 포르마 세라퓨틱스 인크. | 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 |
| MX372964B (es) | 2014-09-19 | 2020-03-27 | Forma Therapeutics Inc | Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh) |
| AU2015317321B2 (en) | 2014-09-19 | 2020-03-12 | Forma Therapeutics, Inc. | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors |
| EP3201185B1 (en) | 2014-09-19 | 2018-11-21 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| US10328064B2 (en) | 2014-12-23 | 2019-06-25 | Fgh Biotech, Inc. | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| US9624216B2 (en) | 2015-04-21 | 2017-04-18 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| ES2912921T3 (es) | 2016-04-29 | 2022-05-30 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
| WO2017223202A1 (en) * | 2016-06-22 | 2017-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
| US11339142B2 (en) | 2016-09-07 | 2022-05-24 | Fgh Biotech, Inc. | Di-substituted pyrazole compounds for the treatment of diseases |
| WO2019146129A1 (ja) * | 2018-01-29 | 2019-08-01 | 富士フイルム株式会社 | イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| US11738018B2 (en) | 2018-05-16 | 2023-08-29 | FORMA Therapeuetics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| US11497743B2 (en) | 2018-05-16 | 2022-11-15 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
| US20210196701A1 (en) | 2018-05-16 | 2021-07-01 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| CA3104760C (en) * | 2018-06-26 | 2023-09-26 | Kpc Pharmaceuticals, Inc. | Benzimidazole derivatives and use thereof as idh1 inhibitors |
| CN109224061B (zh) * | 2018-11-16 | 2022-01-07 | 上海市肺科医院 | 化合物ag120或其药学上可接受的盐在制备预防或治疗结核病的药物中的用途 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| AU2023398924A1 (en) | 2022-12-16 | 2025-06-26 | Karuna Therapeutics, Inc. | Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions |
| CN116284025B (zh) * | 2023-02-20 | 2025-07-04 | 国科大杭州高等研究院 | 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| US20040147561A1 (en) * | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
| CN1774247A (zh) * | 2003-02-14 | 2006-05-17 | 史密丝克莱恩比彻姆公司 | 新的化合物 |
| ATE511843T1 (de) | 2005-04-04 | 2011-06-15 | Eisai R&D Man Co Ltd | Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz |
| WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| MX2008014618A (es) | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
| AU2007275682B2 (en) * | 2006-07-20 | 2012-05-17 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| WO2008079316A1 (en) | 2006-12-20 | 2008-07-03 | Cara Therapeutics, Inc. | Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| EP2525790B1 (en) | 2009-10-21 | 2020-05-27 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| EP2509600B1 (en) | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| ES2704862T3 (es) | 2010-07-16 | 2019-03-20 | Agios Pharmaceuticals Inc | Composiciones terapéuticamente activas y su método de uso |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| AU2012313888B2 (en) | 2011-09-27 | 2016-03-31 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| US9434743B2 (en) * | 2012-03-02 | 2016-09-06 | Takeda Pharmaceutical Company Limited | Indazole derivatives |
| KR102209667B1 (ko) | 2014-09-19 | 2021-01-29 | 포르마 세라퓨틱스 인크. | 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 |
-
2015
- 2015-12-22 CN CN201580076328.4A patent/CN107428690B/zh active Active
- 2015-12-22 EP EP15823901.2A patent/EP3237385B1/en active Active
- 2015-12-22 WO PCT/US2015/067406 patent/WO2016106331A1/en not_active Ceased
- 2015-12-22 ES ES15823901T patent/ES2905564T3/es active Active
- 2015-12-22 JP JP2017534314A patent/JP6901394B2/ja active Active
- 2015-12-22 US US15/538,570 patent/US10703746B2/en active Active
- 2015-12-22 AU AU2015369712A patent/AU2015369712B2/en active Active
- 2015-12-22 CA CA2971872A patent/CA2971872C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531769A5 (enExample) | ||
| IL274816B2 (en) | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | |
| JP2016517417A5 (enExample) | ||
| JP2020515575A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| JP2016525075A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2016501250A5 (enExample) | ||
| JP2011503230A5 (enExample) | ||
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| JP2017528487A5 (enExample) | ||
| JP2013529210A5 (enExample) | ||
| JP2010508338A5 (enExample) | ||
| JP2018534355A5 (enExample) | ||
| RU2017126199A (ru) | Биарильное производное в качестве агониста gpr120 | |
| JP2017536342A5 (enExample) | ||
| JP2020503302A5 (enExample) | ||
| JP2021523933A5 (enExample) | ||
| JP2019529445A5 (enExample) | ||
| JP2013537913A5 (enExample) |